Gene therapy using genetically modified viral vectors
OwnerElizabeth Louise Parrish, Anca Selariuinventors
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for gene therapy by administration of genetically modified viral vectors. Gene therapy vectors can include a cytomegalovirus vector encoding one or more therapeutic donor genes such as human telomerase reverse transcriptase (hTERT). These vectors can be used in exemplary gene therapy methods for maintaining or improving one or more aspects of a recipient's physiological wellness and/or longevity. The recombinant viral vector can be administered or received intranasally or as an injectable therapeutic
Claims20
A method for gene therapy using intranasal administration of genetically modified viral vectors, comprising:
- creating a gene cassette comprising one or more donor genes;
- inserting the gene cassette into a cloning vector and transfecting the cloning vector into a bacterial cell;
- preparing a human-administrable viral vector to include the one or more genes, wherein the human-administrable viral vector is a human cytomegalovirus or a varicella zoster virus;
- preparing a solution containing a therapeutic amount of viral agents comprising the plurality of target genes;
- and
- administering the solution to the subject.
A method for gene therapy using intranasal administration of genetically modified viral vectors, comprising:
- creating a gene cassette comprising one or more donor genes, the one or more donor genes comprising hTERT, hFS344, or both;
- inserting the gene cassette into a cloning vector and transfecting the cloning vector into a bacterial cell;
- preparing a human-administrable viral vector to include the one or more genes, wherein the human-administrable viral vector is a human cytomegalovirus;
- preparing a solution containing a therapeutic amount of viral agents comprising the plurality of target genes;
- and
- administering the solution to the subject.
A method for gene therapy using intranasal administration of genetically modified viral vectors, comprising:
- creating a gene cassette comprising both hTERT and hFS344;
- inserting the gene cassette into a cloning vector and transfecting the cloning vector into a bacterial cell;
- preparing a human-administrable viral vector to include the one or more genes, wherein the human-administrable viral vector is a human cytomegalovirus;
- preparing a solution containing a therapeutic amount of viral agents comprising the plurality of target genes;
- and
- administering the solution to a human subject.
Dependencies are inferred from the claim text.